Antimicrobial Resistance in Vibrios

  • Michael L. Bennish
  • Wasif A. Khan
  • Debasish Saha
Part of the Infectious Disease book series (ID)

This chapter addresses antimicrobial resistance in a genus – Vibrio – that results in two distinct clinical syndromes. One is profound diarrheal disease – cholera – caused by Vibrio cholerae O1 or O139. The other is often the fatal wound infection and sepsis caused by a variety of halophilic (saltloving) vibrios (1) – with V. vulnificus and V. parahaemolyticus perhaps being the most commonly occurring species (2–4) but including infections with V. alginolyticus (5), V. harveyi, V. fl uvialis, and others (6).


Antimicrob Agent Vibrio Cholerae Cholera Outbreak Bull World Health Organ Epidemiol Infect 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Hollis DG, Weaver RE, Baker CN, Thornsberry C. Halophilic Vibrio species isolated from blood cultures. J Clin Microbiol 1976;3:425–431PubMedGoogle Scholar
  2. 2.
    Chiang SR, Chuang YC. Vibrio vulnificus infection: clinical manifestations, pathogenesis, and antimicrobial therapy. J Microbiol Immunol Infect 2003;36:81–88PubMedGoogle Scholar
  3. 3.
    Liu JW, Lee IK, Tang HJ, Ko WC, Lee HC, Liu YC, Hsueh PR, Chuang YC. Prognostic factors and antibiotics in Vibrio vulnificus septicemia. Arch Intern Med 2006;166:2117–2123PubMedCrossRefGoogle Scholar
  4. 4.
    Hally RJ, Rubin RA, Fraimow HS, Hoffman-Terry ML. Fatal Vibrio parahemolyticus septicemia in a patient with cirrhosis. A case report and review of the literature. Dig Dis Sci 1995;40:1257–1260Google Scholar
  5. 5.
    Schmidt U, Chmel H, Cobbs C. Vibrio alginolyticus infections in humans. J Clin Microbiol 1979;10:666–668PubMedGoogle Scholar
  6. 6.
    French GL, Woo ML, Hui YW, Chan KY. Antimicrobial susceptibilities of halophilic vibrios. J Antimicrob Chemother 1989;24:183–194PubMedCrossRefGoogle Scholar
  7. 7.
    Jesudason MV, Lalitha MK, Koshi G. Non 01 Vibrio cholerae in intestinal and extra intestinal infections in Vellore, S. India. Indian J Pathol Microbiol 1991;34:26–29PubMedGoogle Scholar
  8. 8.
    Lesmana M, Subekti DS, Tjaniadi P, Simanjuntak CH, Punjabi NH, Campbell JR, Oyofo BA. Spectrum of vibrio species associated with acute diarrhea in North Jakarta, Indonesia. Diagn Microbiol Infect Dis 2002;43:91–97PubMedCrossRefGoogle Scholar
  9. 9.
    Fuenzalida L, Hernandez C, Toro J, Rioseco ML, Romero J, Espejo RT. Vibrio parahaemolyticus in shellfish and clinical samples during two large epidemics of diarrhoea in southern Chile. Environ Microbiol 2006;8:675–683PubMedCrossRefGoogle Scholar
  10. 10.
    Ananthan S, Dhamodaran S. Toxigenicity & drug sensitivity of Vibrio mimicus isolated from patients with diarrhoea. Indian J Med Res 1996;104:336–341PubMedGoogle Scholar
  11. 11.
    Makino K, Oshima K, Kurokawa K, Yokoyama K, Uda T, Tagomori K, Iijima Y, Najima M, Nakano M, Yamashita A, Kubota Y, Kimura S, Yasunaga T, Honda T, Shinagawa H, Hattori M, Iida T. Genome sequence of Vibrio parahaemolyticus: a pathogenic mechanism distinct from that of V cholerae. Lancet 2003;361:743–749PubMedCrossRefGoogle Scholar
  12. 12.
    Back E, Ljunggren A, Smith H, Jr. Non-cholera Vibrios in Sweden. Lancet 1974;1:723–724PubMedCrossRefGoogle Scholar
  13. 13.
    Cholera 2005. Wkly Epidemiol Rec 2006;81:297–307Google Scholar
  14. 14.
    Siddique AK, Salam A, Islam MS, Akram K, Majumdar RN, Zaman K, Fronczak N, Laston S. Why treatment centres failed to prevent cholera deaths among Rwandan refugees in Goma, Zaire. Lancet 1995;345:359–361PubMedCrossRefGoogle Scholar
  15. 15.
    Agtini MD, Soeharno R, Lesmana M, Punjabi NH, Simanjuntak C, Wangsasaputra F, Nurdin D, Pulungsih SP, Rofiq A, Santoso H, Pujarwoto H, Sjahrurachman A, Sudarmono P, von Seidlein L, Deen JL, Ali M, Lee H, Kim DR, Han O, Park JK, Suwandono A, Ingerani, Oyofo BA, Campbell JR, Beecham HJ, Corwin AL, Clemens JD. The burden of diarrhoea, shigellosis, and cholera in North Jakarta, Indonesia: findings from 24 months surveillance. BMC Infect Dis 2005;5:89PubMedCrossRefGoogle Scholar
  16. 16.
    Sur D, Deen JL, Manna B, Niyogi SK, Deb AK, Kanungo S, Sarkar BL, Kim DR, Danovaro-Holliday MC, Holliday K, Gupta VK, Ali M, von Seidlein L, Clemens JD, Bhattacharya SK. The burden of cholera in the slums of Kolkata, India: data from a prospective, community based study. Arch Dis Child 2005;90:1175–1181PubMedCrossRefGoogle Scholar
  17. 17.
    Khan WA, Bennish ML, Seas C, Khan EH, Ronan A, Dhar U, Busch W, Salam MA. Randomised controlled comparison of single-dose ciprofloxacin and doxycycline for cholera caused by Vibrio cholerae 01 or 0139. Lancet 1996;348:296–300PubMedCrossRefGoogle Scholar
  18. 18.
    Khan WA, Saha D, Rahman A, Salam MA, Bogaerts J, Bennish ML. Comparison of single-dose azithromycin and 12-dose, 3-day erythromycin for childhood cholera: a randomised, double-blind trial. Lancet 2002;360:1722–1727PubMedCrossRefGoogle Scholar
  19. 19.
    Saha D, Karim MM, Khan WA, Ahmed S, Salam MA, Bennish ML. Single-dose azithromycin for the treatment of cholera in adults. N Engl J Med 2006;354:2452–2462PubMedCrossRefGoogle Scholar
  20. 20.
    Saha D, Khan WA, Karim MM, Chowdhury HR, Salam MA, Bennish ML. Single-dose ciprofloxacin versus 12-dose erythromycin for childhood cholera: a randomised controlled trial. Lancet 2005;366:1085–1093PubMedCrossRefGoogle Scholar
  21. 21.
    Alam AN, Alam NH, Ahmed T, Sack DA. Randomised double blind trial of single dose doxycycline for treating cholera in adults. BMJ 1990;300:1619–1621PubMedCrossRefGoogle Scholar
  22. 22.
    Sack DA, Islam S, Rabbani H, Islam A. Single-dose doxycycline for cholera. Antimicrob Agents Chemother 1978;14:462–464PubMedGoogle Scholar
  23. 23.
    Greenough WB, III, Gordon RS, Jr, Rosenberg IS, Davies BI, Benenson AS. Tetracycline in the treatment of cholera. Lancet 1964;41:355–357CrossRefGoogle Scholar
  24. 24.
    Lindenbaum J, Greenough WB, Islam MR. Antibiotic therapy of cholera in children. Bull World Health Organ 1967;37:529–538PubMedGoogle Scholar
  25. 25.
    Lindenbaum J, Greenough WB, Islam MR. Antibiotic therapy of cholera. Bull World Health Organ 1967;36:871–883PubMedGoogle Scholar
  26. 26.
    Aidara A, Koblavi S, Boye CS, Raphenon G, Gassama A, Grimont F, Grimont PA. Phenotypic and genotypic characterization of Vibrio cholerae isolates from a recent cholera outbreak in Senegal: comparison with isolates from Guinea-Bissau. Am J Trop Med Hyg 1998;58:163–167PubMedGoogle Scholar
  27. 27.
    Dalsgaard A, Forslund A, Sandvang D, Arntzen L, Keddy K. Vibrio cholerae O1 outbreak isolates in Mozambique and South Africa in 1998 are multiple-drug resistant, contain the SXT element and the aadA2 gene located on class 1 integrons. J Antimicrob Chemother 2001;48:827–838PubMedCrossRefGoogle Scholar
  28. 28.
    Das S, Gupta S. Diversity of Vibrio cholerae strains isolated in Delhi, India, during 1992–2000. J Health Popul Nutr 2005;23:44–51PubMedGoogle Scholar
  29. 29.
    Dhar U, Bennish ML, Khan WA, Seas C, Huq Khan E, Albert MJ, Abdus Salam M. Clinical features, antimicrobial susceptibility and toxin production in Vibrio cholerae O139 infection: comparison with V. cholerae 01 infection. Trans R Soc Trop Med Hyg 1996;90:402–405PubMedCrossRefGoogle Scholar
  30. 30.
    Garg P, Chakraborty S, Basu I, Datta S, Rajendran K, Bhattacharya T, Yamasaki S, Bhattacharya SK, Takeda Y, Nair GB, Ramamurthy T. Expanding multiple antibiotic resistance among clinical strains of Vibrio cholerae isolated from 1992–7 in Calcutta, India. Epidemiol Infect 2000;124:393–399PubMedCrossRefGoogle Scholar
  31. 31.
    Garg P, Sinha S, Chakraborty R, Bhattacharya SK, Nair GB, Ramamurthy T, Takeda Y. Emergence of fluoroquinolone-resistant strains of Vibrio cholerae O1 biotype El Tor among hospitalized patients with cholera in Calcutta, India. Antimicrob Agents Chemother 2001;45:1605–1606PubMedCrossRefGoogle Scholar
  32. 32.
    Scrascia M, Forcillo M, Maimone F, Pazzani C. Susceptibility to rifaximin of Vibrio cholerae strains from different geographical areas. J Antimicrob Chemother 2003;52:303–305PubMedCrossRefGoogle Scholar
  33. 33.
    Urassa WK, Mhando YB, Mhalu FS, Mjonga SJ. Antimicrobial susceptibility pattern of Vibrio cholerae O1 strains during two cholera outbreaks in Dar es Salaam, Tanzania. East Afr Med J 2000;77:350–353PubMedGoogle Scholar
  34. 34.
    Ehara M, Nguyen BM, Nguyen DT, Toma C, Higa N, Iwanaga M. Drug susceptibility and its genetic basis in epidemic Vibrio cholerae O1 in Vietnam. Epidemiol Infect 2004;132:595–600PubMedCrossRefGoogle Scholar
  35. 35.
    Mohanty S, Kapil A, Das BK. Seasonality and antimicrobial resistance pattern of Vibrio cholerae in a tertiary care hospital of North India. Trop Doct 2004;34:249–251PubMedGoogle Scholar
  36. 36.
    Mwansa JC, Mwaba J, Lukwesa C, Bhuiyan NA, Ansaruzamman M, Ramamurthy T, Alam M, Balakrish Nair G. Multiply antibiotic-resistant Vibrio cholerae O1 biotype El Tor strains emerge during cholera outbreaks in Zambia. Epidemiol Infect 2006:1–7Google Scholar
  37. 37.
    Yamamoto T, Nair GB, Albert MJ, Parodi CC, Takeda Y. Survey of in vitro susceptibilities of Vibrio cholerae O1 and O139 to antimicrobial agents. Antimicrob Agents Chemother 1995;39:241–244PubMedGoogle Scholar
  38. 38.
    Israil A, Nacescu N, Cedru CL, Ciufecu C, Damian M. Changes in Vibrio cholerae O1 strains isolated in Romania during 1977–95. Epidemiol Infect 1998;121:253–258PubMedCrossRefGoogle Scholar
  39. 39.
    Sheikh A, Khan A, Malik T, Fisher-Hoch SP. Cholera in a developing megacity; Karachi, Pakistan. Epidemiol Infect 1997;119:287–292PubMedCrossRefGoogle Scholar
  40. 40.
    Mishra M, Mohammed F, Akulwar SL, Katkar VJ, Tankhiwale NS, Powar RM. Re-emergence of El Tor Vibrio in outbreak of cholera in & around Nagpur. Indian J Med Res 2004;120:478–480PubMedGoogle Scholar
  41. 41.
    Ryan ET, Dhar U, Khan WA, Salam MA, Faruque AS, Fuchs GJ, Calderwood SB, Bennish ML. Mortality, morbidity, and microbiology of endemic cholera among hospitalized patients in Dhaka, Bangladesh. Am J Trop Med Hyg 2000;63:12–20PubMedGoogle Scholar
  42. 42.
    Ulusarac O, Carter E. Varied clinical presentations of Vibrio vulnificus infections: a report of four unusual cases and review of the literature. South Med J 2004;97:163–168PubMedCrossRefGoogle Scholar
  43. 43.
    Chuang YC, Yuan CY, Liu CY, Lan CK, Huang AH. Vibrio vulnificus infection in Taiwan: report of 28 cases and review of clinical manifestations and treatment. Clin Infect Dis 1992;15:271–276PubMedGoogle Scholar
  44. 44.
    Shapiro RL, Altekruse S, Hutwagner L, Bishop R, Hammond R, Wilson S, Ray B, Thompson S, Tauxe RV, Griffin PM. The role of Gulf Coast oysters harvested in warmer months in Vibrio vulnificus infections in the United States, 1988–1996. Vibrio Working Group. J Infect Dis 1998;178:752–759PubMedCrossRefGoogle Scholar
  45. 45.
    Klontz KC, Lieb S, Schreiber M, Janowski HT, Baldy LM, Gunn RA. Syndromes of Vibrio vulnificus infections. Clinical and epidemiologic features in Florida cases, 1981–1987. Ann Intern Med 1988;109:318–323PubMedGoogle Scholar
  46. 46.
    Hoge CW, Watsky D, Peeler RN, Libonati JP, Israel E, Morris JG, Jr. Epidemiology and spectrum of Vibrio infections in a Chesapeake Bay community. J Infect Dis 1989;160:985–993PubMedGoogle Scholar
  47. 47.
    Oliver JD. Wound infections caused by Vibrio vulnificus and other marine bacteria. Epidemiol Infect 2005;133:383–391PubMedCrossRefGoogle Scholar
  48. 48.
    Tang HJ, Chang MC, Ko WC, Huang KY, Lee CL, Chuang YC. In vitro and in vivo activities of newer fluoroquinolones against Vibrio vulnificus. Antimicrob Agents Chemother 2002;46:3580–3584PubMedCrossRefGoogle Scholar
  49. 49.
    Kim DM, Lym Y, Jang SJ, Han H, Kim YG, Chung CH, Hong SP. In vitro efficacy of the combination of ciprofloxacin and cefotaxime against Vibrio vulnificus. Antimicrob Agents Chemother 2005;49:3489–3491PubMedCrossRefGoogle Scholar
  50. 50.
    Zanetti S, Spanu T, Deriu A, Romano L, Sechi LA, Fadda G. In vitro susceptibility of Vibrio spp. isolated from the environment. Int J Antimicrob Agents 2001;17:407–409CrossRefGoogle Scholar
  51. 51.
    Vibrio vulnificus infections associated with eating raw oysters – Los Angeles, 1996. MMWR Morb Mortal Wkly Rep 1996;45:621–624Google Scholar
  52. 52.
    Joseph SW, DeBell RM, Brown WP. In vitro response to chloram-phenicol, tetracycline, ampicillin, gentamicin, and beta-lactamase production by halophilic Vibrios from human and environmental sources. Antimicrob Agents Chemother 1978;13:244–248PubMedGoogle Scholar
  53. 53.
    Ottaviani D, Bacchiocchi I, Masini L, Leoni F, Carraturo A, Giammarioli M, Sbaraglia G. Antimicrobial susceptibility of potentially pathogenic halophilic vibrios isolated from seafood. Int J Antimicrob Agents 2001;18:135–140PubMedCrossRefGoogle Scholar
  54. 54.
    Kobari K, Takakura I, Nakatomi M, Sogame S, Uylangco C. Antibiotic-resistant strains of E1 Tor vibrio in the Philippines and the use of furalazine for chemotherapy. Bull World Health Organ 1970;43:365–371PubMedGoogle Scholar
  55. 55.
    O'Grady F, Lewis MJ, Pearson NJ. Global surveillance of antibiotic sensitivity of Vibrio cholerae. Bull World Health Organ 1976;54:181–185PubMedGoogle Scholar
  56. 56.
    Glass RI, Huq I, Alim AR, Yunus M. Emergence of multiply antibiotic-resistant Vibrio cholerae in Bangladesh. J Infect Dis 1980;142:939–942PubMedGoogle Scholar
  57. 57.
    Glass RI, Huq MI, Lee JV, Threlfall EJ, Khan MR, Alim AR, Rowe B, Gross RJ. Plasmid-borne multiple drug resistance in Vibrio cholerae serogroup O1, biotype El Tor: evidence for a point-source outbreak in Bangladesh. J Infect Dis 1983;147:204–209PubMedGoogle Scholar
  58. 58.
    Towner KJ, Pearson NJ, Mhalu FS, O'Grady F. Resistance to antimicrobial agents of Vibrio cholerae E1 Tor strains isolated during the fourth cholera epidemic in the United Republic of Tanzania. Bull World Health Organ 1980;58:747–751PubMedGoogle Scholar
  59. 59.
    Olukoya DK, Ogunjimi AA, Abaelu AM. Plasmid profiles and antimicrobial susceptibility patterns of Vibrio cholerae O1 strain isolated during a recent outbreak in Nigeria. J Diarrhoeal Dis Res 1995;13:118–121PubMedGoogle Scholar
  60. 60.
    Zachariah R, Harries AD, Arendt V, Nchingula D, Chimtulo F, Courteille O, Kirpach P. Characteristics of a cholera outbreak, patterns of Vibrio cholerae and antibiotic susceptibility testing in rural Malawi. Trans R Soc Trop Med Hyg 2002;96:39–40PubMedCrossRefGoogle Scholar
  61. 61.
    Finch MJ, Morris JG, Jr, Kaviti J, Kagwanja W, Levine MM. Epidemiology of antimicrobial resistant cholera in Kenya and East Africa. Am J Trop Med Hyg 1988;39:484–490PubMedGoogle Scholar
  62. 62.
    Khan WA, Dhar U, Begum M, Salam MA, Bardhan PK, Mahalanabis D. Antimicrobial treatment of adults with cholera due to Vibrio cholerae 0139 (synonym Bengal). Drugs 1995;49 Suppl 2:460–462PubMedCrossRefGoogle Scholar
  63. 63.
    Basu A, Garg P, Datta S, Chakraborty S, Bhattacharya T, Khan A, Ramamurthy S, Bhattacharya SK, Yamasaki S, Takeda Y, Nair GB. Vibrio cholerae O139 in Calcutta, 1992–1998: incidence, antibiograms, and genotypes. Emerg Infect Dis 2000;6:139–147PubMedCrossRefGoogle Scholar
  64. 64.
    Mukhopadhyay AK, Garg S, Nair GB, Kar S, Ghosh RK, Pajni S, Ghosh A, Shimada T, Takeda T, Takeda Y. Biotype traits and antibiotic susceptibility of Vibrio cholerae serogroup O1 before, during and after the emergence of the O139 serogroup. Epidemiol Infect 1995;115:427–434PubMedCrossRefGoogle Scholar
  65. 65.
    Niyogi SK, Sengupta PG, Bhattacharya SK, Garg S, Mukhapadhayay AK, Nair GB. Emergence of furazolidone and cotrimoxazole resistant Vibrio cholerae 01 in eastern India. J Infect 1995;30:265–266PubMedCrossRefGoogle Scholar
  66. 66.
    Ramamurthy T, Rajendran K, Garg P, Shimada T, Basu A, Chowdhury NR, Nandy RK, Yamasaki S, Bhattacharya SK, Takeda Y, Nair GB. Cluster-analysis & patterns of dissemination of multidrug resistance among clinical strains of Vibrio cholerae in Calcutta, India. Indian J Med Res 2000;112:78–85PubMedGoogle Scholar
  67. 67.
    Jesudason MV, Balaji V, Thomson CJ. Quinolone susceptibility of Vibrio cholerae O1 & O139 isolates from Vellore. Indian J Med Res 2002;116:96–98PubMedGoogle Scholar
  68. 68.
    Jesudason M V, Saaya R. Resistance of Vibrio cholerae 01 to nalidixic acid. Indian J Med Res 1997;105:153–154PubMedGoogle Scholar
  69. 69.
    Dalsgaard A, Forslund A, Bodhidatta L, Serichantalergs O, Pitarangsi C, Pang L, Shimada T, Echeverria P. A high proportion of Vibrio cholerae strains isolated from children with diarrhoea in Bangkok, Thailand are multiple antibiotic resistant and belong to heterogenous non-O1, non-O139 O-serotypes. Epidemiol Infect 1999;122:217–226PubMedCrossRefGoogle Scholar
  70. 70.
    Tabtieng R, Wattanasri S, Echeverria P, Seriwatana J, Bodhidatta L, Chatkaeomorakot A, Rowe B. An epidemic of Vibrio cholerae el tor Inaba resistant to several antibiotics with a conjugative group C plasmid coding for type II dihydrofolate reductase in Thailand. Am J Trop Med Hyg 1989;41:680–686PubMedGoogle Scholar
  71. 71.
    Yamamoto T, Nair GB, Takeda Y. Emergence of tetracycline resistance due to a multiple drug resistance plasmid in Vibrio cholerae O139. FEMS Immunol Med Microbiol 1995;11:131–136PubMedCrossRefGoogle Scholar
  72. 72.
    Bhattacharya MK, Ghosh S, Mukhopadhyay AK, Deb A, Bhattacharya SK. Outbreak of cholera caused by Vibrio cholerae 01 intermediately resistant to norfloxacin at Malda, West Bengal. J Indian Med Assoc 2000;98:389–390PubMedGoogle Scholar
  73. 73.
    Mukhopadhyay AK, Basu I, Bhattacharya SK, Bhattacharya MK, Nair GB. Emergence of fluoroquinolone resistance in strains of Vibrio cholerae isolated from hospitalized patients with acute diarrhea in Calcutta, India. Antimicrob Agents Chemother 1998;42:206–207PubMedGoogle Scholar
  74. 74.
    Sundaram SP, Revathi J, Sarkar BL, Bhattacharya SK. Bacteriological profile of cholera in Tamil Nadu (1980–2001). Indian J Med Res 2002;116:258–263PubMedGoogle Scholar
  75. 75.
    Sabeena F, Thirivikramji G, Radhakutty G, Indu P, Singh DV. In vitro susceptibility of Vibrio cholerae O1 biotype El Tor strains associated with an outbreak of cholera in Kerala, Southern India. J Antimicrob Chemother 2001;47:361–362PubMedCrossRefGoogle Scholar
  76. 76.
    Radu S, Vincent M, Apun K, Abdul-Rahim R, Benjamin PG, Yuherman, Rusul G. Molecular characterization of Vibrio cholerae O1 outbreak strains in Miri, Sarawak (Malaysia). Acta Trop 2002;83:169–176PubMedCrossRefGoogle Scholar
  77. 77.
    Srifuenfung S, Komolpis P, Yungyuen T, Techachaiwiwat W, Tribuddharat C. Prevalence of Vibrio species isolated from fecal specimens of patients with diarrhea in Siriraj Hospital during 1994–2001. J Infect Dis Antimicrob Agents 2004;21:83–88Google Scholar
  78. 78.
    Falbo V, Carattoli A, Tosini F, Pezzella C, Dionisi AM, Luzzi I. Antibiotic resistance conferred by a conjugative plasmid and a class I integron in Vibrio cholerae O1 El Tor strains isolated in Albania and Italy. Antimicrob Agents Chemother 1999;43:693–696PubMedGoogle Scholar
  79. 79.
    Campos LC, Zahner V, Avelar KE, Alves RM, Pereira DS, Vital BJ, Freitas FS, Salles CA, Karaolis DK. Genetic diversity and antibiotic resistance of clinical and environmental Vibrio cholerae suggests that many serogroups are reservoirs of resistance. Epidemiol Infect 2004;132:985–992PubMedCrossRefGoogle Scholar
  80. 80.
    Dubon JM, Palmer CJ, Ager AL, Shor-Posner G, Baum MK. Emergence of multiple drug-resistant Vibrio cholerae O1 in San Pedro Sula, Honduras. Lancet 1997;349:924PubMedCrossRefGoogle Scholar
  81. 81.
    Weber JT, Mintz ED, Canizares R, Semiglia A, Gomez I, Sempertegui R, Davila A, Greene KD, Puhr ND, Cameron DN, et al. Epidemic cholera in Ecuador: multidrug-resistance and transmission by water and seafood. Epidemiol Infect 1994;112:1–11PubMedCrossRefGoogle Scholar
  82. 82.
    Large epidemic of cholera-like disease in Bangladesh caused by Vibrio cholerae O139 synonym Bengal. Cholera Working Group, International Centre for Diarrhoeal Diseases Research, Bangladesh. Lancet 1993;342:387–390CrossRefGoogle Scholar
  83. 83.
    Waldor MK, Mekalanos JJ. Emergence of a new cholera pandemic: molecular analysis of virulence determinants in Vibrio cholerae O139 and development of a live vaccine prototype. J Infect Dis 1994;170:278–283PubMedGoogle Scholar
  84. 84.
    Waldor MK, Mekalanos JJ. Vibrio cholerae O139 specific gene sequences. Lancet 1994;343:1366PubMedCrossRefGoogle Scholar
  85. 85.
    Waldor MK, Tschape H, Mekalanos JJ. A new type of conjugative transposon encodes resistance to sulfamethoxazole, trimethoprim, and streptomycin in Vibrio cholerae 0139. J Bacteriol 1996;178:4157–4165PubMedGoogle Scholar
  86. 86.
    Hochhut B, LotfiY, Mazel D, Faruque SM, Woodgate R, Waldor MK. Molecular analysis of antibiotic resistance gene clusters in Vibrio cholerae O139 and O1 SXT constins. Antimicrob Agents Chemother 2001;45:2991–3000PubMedCrossRefGoogle Scholar
  87. 87.
    Faruque SM, Abdul Alim AR, Rahman MM, Siddique AK, Sack RB, Albert MJ. Clonal relationships among classical Vibrio cholerae O1 strains isolated between 1961 and 1992 in Bangladesh. J Clin Microbiol 1993;31:2513–2516PubMedGoogle Scholar
  88. 88.
    Faruque SM, Ahmed KM, Abdul Alim AR, Qadri F, Siddique AK, Albert MJ. Emergence of a new clone of toxigenic Vibrio cholerae O1 biotype El Tor displacing V. cholerae O139 Bengal in Bangladesh. J Clin Microbiol 1997;35:624–630PubMedGoogle Scholar
  89. 89.
    Faruque SM, Saha MN, Asadulghani, Sack DA, Sack RB, Takeda Y, Nair GB. The O139 serogroup of Vibrio cholerae comprises diverse clones of epidemic and nonepidemic strains derived from multiple V. cholerae O1 or non-O1 progenitors. J Infect Dis 2000;182:1161–1168PubMedCrossRefGoogle Scholar
  90. 90.
    Scrascia M, Maimone F, Mohamud KA, Materu SF, Grimont F, Grimont PA, Pazzani C. Clonal relationship among Vibrio cholerae O1 El Tor strains causing the largest cholera epidemic in Kenya in the late 1990s. J Clin Microbiol 2006;44:3401–3404PubMedCrossRefGoogle Scholar
  91. 91.
    Dalsgaard A, Forslund A, Tam N V, Vinh DX, Cam PD. Cholera in Vietnam: changes in genotypes and emergence of class I integrons containing aminoglycoside resistance gene cassettes in Vibrio cholerae O1 strains isolated from 1979 to 1996. J Clin Microbiol 1999;37:734–741PubMedGoogle Scholar
  92. 92.
    Ceccarelli D, Salvia AM, Sami J, Cappuccinelli P, Colombo MM. New cluster of plasmid-located class 1 integrons in Vibrio cholerae O1 and a dfrA15 cassette-containing integron in Vibrio parahaemolyticus isolated in Angola. Antimicrob Agents Chemother 2006;50:2493–2499PubMedCrossRefGoogle Scholar
  93. 93.
    Vora GJ, Meador CE, Bird MM, Bopp CA, Andreadis JD, Stenger DA. Microarray-based detection of genetic heterogeneity, antimicrobial resistance, and the viable but nonculturable state in human pathogenic Vibrio spp. Proc Natl Acad Sci U S A 2005;102:19109–19114PubMedCrossRefGoogle Scholar
  94. 94.
    Iwanaga M, Toma C, Miyazato T, Insisiengmay S, Nakasone N, Ehara M. Antibiotic resistance conferred by a class I integron and SXT constin in Vibrio cholerae O1 strains isolated in Laos. Antimicrob Agents Chemother 2004;48:2364–2369PubMedCrossRefGoogle Scholar
  95. 95.
    Amita, Chowdhury SR, Thungapathra M, Ramamurthy T, Nair GB, Ghosh A. Class I integrons and SXT elements in El Tor strains isolated before and after 1992 Vibrio cholerae O139 outbreak, Calcutta, India. Emerg Infect Dis 2003;9:500–502PubMedGoogle Scholar
  96. 96.
    Toma C, Nakasone N, Song T, Iwanaga M. Vibrio cholerae SXT element, Laos. Emerg Infect Dis 2005;11:346–347PubMedGoogle Scholar
  97. 97.
    Baranwal S, Dey K, Ramamurthy T, Nair GB, Kundu M. Role of active efflux in association with target gene mutations in fluoroquinolone resistance in clinical isolates of Vibrio cholerae. Antimicrob Agents Chemother 2002;46:2676–2678PubMedCrossRefGoogle Scholar
  98. 98.
    Colmer JA, Fralick JA, Hamood AN. Isolation and characterization of a putative multidrug resistance pump from Vibrio cholerae. Mol Microbiol 1998;27:63–72PubMedCrossRefGoogle Scholar
  99. 99.
    Krishna B V, Patil AB, Chandrasekhar MR. Fluoroquinolone-resistant Vibrio cholerae isolated during a cholera outbreak in India. Trans R Soc Trop Med Hyg 2006;100:224–226PubMedCrossRefGoogle Scholar
  100. 100.
    Albert MJ, Bhuiyan NA, Talukder KA, Faruque AS, Nahar S, Faruque SM, Ansaruzzaman M, Rahman M. Phenotypic and genotypic changes in Vibrio cholerae O139 Bengal. J Clin Microbiol 1997;35:2588–2592PubMedGoogle Scholar
  101. 101.
    Faruque SM, Chowdhury N, Kamruzzaman M, Ahmad QS, Faruque AS, Salam MA, Ramamurthy T, Nair GB, Weintraub A, Sack DA. Reemergence of epidemic Vibrio cholerae O139, Bangladesh. Emerg Infect Dis 2003;9:1116–1122PubMedGoogle Scholar
  102. 102.
    Jabeen K, Hasan R. Re-emergence of Vibrio cholerae O139 in Pakistan: report from a tertiary care hospital. J Pak Med Assoc 2003;53:335–338PubMedGoogle Scholar
  103. 103.
    Saha D, Khan WA, Ahmed S, Faruque ASG, Salam MA, Bennish ML. Resurgent, multiresistant V. cholerae O1 in Bangladesh. In: 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA; 2006Google Scholar
  104. 104.
    Khan WA, Saha D, Ahmed S, Salam MA, Bennish ML. Identification and treatment of V. cholerae O1 with diminished susceptibility to ciprofloxacin. In: 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA; 2006Google Scholar
  105. 105.
    Crump JA, Barrett TJ, Nelson JT, Angulo FJ. Reevaluating fluoroquinolone breakpoints for Salmonella enterica serotype Typhi and for non-Typhi salmonellae. Clin Infect Dis 2003;37:75–81PubMedCrossRefGoogle Scholar
  106. 106.
    Knapp JS, Hale JA, Neal SW, Wintersheid K, Rice RJ, Whittington WL. Proposed criteria for interpretation of susceptibilities of strains of Neisseria gonorrhoeae to ciprofloxacin, ofloxacin, enoxacin, lomefloxacin, and norfloxacin. Antimicrob Agents Chemother 1995;39:2442–2445PubMedGoogle Scholar
  107. 107.
    Bennish ML. Cholera: pathophysiology, clinical features, and treatment. In: Wachsmuth IK, Blake PA, Olsvik O, eds. Vibrio cholerae and Cholera Molecular to Global Perspectives. Washington, DC: ASM Press; 1994:229–256Google Scholar
  108. 108.
    Karchmer AW, Curlin GT, Huq MI, Hirschhorn N. Furazolidone in paediatric cholera. Bull World Health Organ 1970;43:373–378PubMedGoogle Scholar
  109. 109.
    World Health Organization. The Treatment of Diarrhoea: A Manual for Physicians and Other Senior Health Workers. (accessed 1 February 2007); 2005
  110. 110.
    Centers for Disease Control and Prevention Atlanta Georgia. Laboratory Methods for the Diagnosis of Epidemic Dysentery and Cholera; 1999Google Scholar
  111. 111.
    Bacterial agents of enteric diseases of public health concern: Salmonella serotype typhi, Shigella, Vibrio cholerae. In: Manual for the Laboratory Identification and Antimicrobial Susceptibility Testing of Bacterial Pathogens of Public Health Importance in the Developing World. Geneva: World Health Organization 2003;103–162Google Scholar
  112. 112.
    Sciortino C V, Johnson JA, Hamad A. Vitek system antimicrobial susceptibility testing of O1, O139, and non-O1 Vibrio cholerae. J Clin Microbiol 1996;34:897–900PubMedGoogle Scholar
  113. 113.
    Khan AM, von Gierke U, Hossain MS, Fuchs GJ. Tetracycline in the treatment of cholera caused by Vibrio cholerae O1 resistant to the drug in vitro. J Health Popul Nutr 2003;21:76–78PubMedGoogle Scholar
  114. 114.
    Jiang ZD, Ke S, Palazzini E, Riopel L, Dupont H. In vitro activity and fecal concentration of rifaximin after oral administration. Antimicrob Agents Chemother 2000;44:2205–2206PubMedCrossRefGoogle Scholar
  115. 115.
    DuPont HL, Jiang ZD, Ericsson CD, Adachi JA, Mathewson JJ, DuPont MW, Palazzini E, Riopel LM, Ashley D, Martinez-Sandoval F. Rifaximin versus ciprofloxacin for the treatment of traveler's diarrhea: a randomized, double-blind clinical trial. Clin Infect Dis 2001;33:1807–1815PubMedCrossRefGoogle Scholar
  116. 116.
    Wenzel RP. The antibiotic pipeline — challenges, costs, and values. N Engl J Med 2004;351:523–526PubMedCrossRefGoogle Scholar
  117. 117.
    Hung DT, Shakhnovich EA, Pierson E, Mekalanos JJ. Small-molecule inhibitor of Vibrio cholerae virulence and intestinal colonization. Science 2005;310:670–674PubMedCrossRefGoogle Scholar
  118. 118.
    Waldor MK. Disarming pathogens — a new approach for antibiotic development. N Engl J Med 2006;354:296–297PubMedCrossRefGoogle Scholar
  119. 119.
    Guerrant RL. Cholera — still teaching hard lessons. N Engl J Med 2006;354:2500–2502PubMedCrossRefGoogle Scholar
  120. 120.
    MacDonald R. Access to clean water in rural Africa is inadequate. BMJ 2005;331:70PubMedCrossRefGoogle Scholar
  121. 121.
    Mukherjee A, Sengupta MK, Hossain MA, Ahamed S, Das B, Nayak B, Lodh D, Rahman MM, Chakraborti D. Arsenic contamination in groundwater: a global perspective with emphasis on the Asian scenario. J Health Popul Nutr 2006;24:142–163PubMedGoogle Scholar
  122. 122.
    Colwell RR, Huq A, Islam MS, Aziz KMA, Yunus M, Khan NH, Mahmud A, Sack RB, Nair GB, Chakraborty J, Sack DA, Russek-Cohen E. Reduction of cholera in Bangladeshi villages by simple filtration. Proc Natl Acad Sci U S A 2003;100:1051–1055PubMedCrossRefGoogle Scholar
  123. 123.
    Quick RE, Venczel LV, Gonzalez O, Mintz ED, Highsmith AK, Espada A, Damiani E, Bean NH, De Hannover EH, Tauxe RV. Narrow-mouthed water storage vessels and in situ chlorination in a Bolivian community: a simple method to improve drinking water quality. Am J Trop Med Hyg 1996;54:511–516PubMedGoogle Scholar
  124. 124.
    Clasen TF, Brown J, Collin S, Suntura O, Cairncross S. Reducing diarrhea through the use of household-based ceramic water filters: a randomized, controlled trial in rural Bolivia. Am J Trop Med Hyg 2004;70:651–657PubMedGoogle Scholar
  125. 125.
    Radu S, Elhadi N, Hassan Z, Rusul G, Lihan S, Fifadara N, Yuherman, Purwati E. Characterization of Vibrio vulnificus isolated from cockles (Anadara granosa): antimicrobial resistance, plasmid profiles and random amplification of polymorphic DNA analysis. FEMS Microbiol Lett 1998;165:139–143PubMedCrossRefGoogle Scholar
  126. 126.
    Bowdre JH, Hull JH, Cocchetto DM. Antibiotic efficacy against Vibrio vulnificus in the mouse: superiority of tetracycline. J Pharmacol Exp Ther 1983;225:595–598PubMedGoogle Scholar
  127. 127.
    Molitoris E, Joseph SW, Krichevsky MI, Sindhuhardja W, Colwell RR. Characterization and distribution of Vibrio alginolyticus and Vibrio parahaemolyticus isolated in Indonesia. Appl Environ Microbiol 1985;50:1388–1394PubMedGoogle Scholar
  128. 128.
    Morris JG, Jr, Tenney JH, Drusano GL. In vitro susceptibility of pathogenic Vibrio species to norfloxacin and six other antimicrobial agents. Antimicrob Agents Chemother 1985;28:442–445PubMedGoogle Scholar
  129. 129.
    Su BA, Tang HJ, Wang YY, Liu YC, Ko WC, Liu CY, Chuang YC. In vitro antimicrobial effect of cefazolin and cefotaxime combined with minocycline against Vibrio cholerae non-O1 non-O139. J Microbiol Immunol Infect 2005;38:425–429PubMedGoogle Scholar
  130. 130.
    do Nascimento SM, dos Fernandes Vieira RH, Theophilo GN, Dos Prazeres Rodrigues D, Vieira GH. Vibrio vulnificus as a health hazard for shrimp consumers. Rev Inst Med Trop Sao Paulo 2001;43:263–266PubMedGoogle Scholar
  131. 131.
    Chuang YC, Liu JW, Ko WC, Lin KY, Wu JJ, Huang KY. In vitro synergism between cefotaxime and minocycline against Vibrio vulnificus. Antimicrob Agents Chemother 1997;41:2214–2217PubMedGoogle Scholar
  132. 132.
    Chuang YC, Ko WC, Wang ST, Liu JW, Kuo CF, Wu JJ, Huang K Y. Minocycline and cefotaxime in the treatment of experimental murine Vibrio vulnificus infection. Antimicrob Agents Chemother 1998;42:1319–1322PubMedGoogle Scholar
  133. 133.
    Jorgensen JH, Hindler JF. New consensus guidelines from the Clinical and Laboratory Standards Institute for antimicrobial susceptibility testing of infrequently isolated or fastidious bacteria. Clin Infect Dis 2007;44:280–286PubMedCrossRefGoogle Scholar
  134. 134.
    Clinical and Laboratory Standards Institute. Methods for antimicrobial dilution and disk susceptibility testing of infrequently isolated or fastidious bacteria. Approved standard M45-A. Wayne, PA: Clinical and Laboratory Standards Institute; 2006Google Scholar
  135. 135.
    Mouzin E, Mascola L, Tormey MP, Dassey DE. Prevention of Vibrio vulnificus infections. Assessment of regulatory educational strategies. JAMA 1997;278:576–578PubMedCrossRefGoogle Scholar
  136. 136.
    Osaka K, Komatsuzaki M, Takahashi H, Sakano S, Okabe N. Vibrio vulnificus septicaemia in Japan: an estimated number of infections and physicians' knowledge of the syndrome. Epidemiol Infect 2004;132:993–996PubMedCrossRefGoogle Scholar
  137. 137.
    Roy SK, Islam A, Ali R, Islam KE, Khan RA, Ara SH, Saifuddin NM, Fuchs GJ. A randomized clinical trial to compare the efficacy of erythromycin, ampicillin and tetracycline for the treatment of cholera in children. Trans R Soc Trop Med Hyg 1998;92:460–462PubMedCrossRefGoogle Scholar
  138. 138.
    Khan WA, Begum M, Salam MA, Bardhan PK, Islam MR, Mahalanabis D. Comparative trial of five antimicrobial compounds in the treatment of cholera in adults. Trans R Soc Trop Med Hyg 1995;89:103–106PubMedCrossRefGoogle Scholar
  139. 139.
    Gotuzzo E, Seas C, Echevarria J, Carrillo C, Mostorino R, Ruiz R. Ciprofloxacin for the treatment of cholera: a randomized, double-blind, controlled clinical trial of a single daily dose in Peruvian adults. Clin Infect Dis 1995;20:1485–1490PubMedGoogle Scholar
  140. 140.
    Kabir I, Khan WA, Haider R, Mitra AK, Alam AN. Erythromycin and trimethoprim—sulphamethoxazole in the treatment of cholera in children. J Diarrhoeal Dis Res 1996;14:243–247PubMedGoogle Scholar
  141. 141.
    Islam MR. Single dose tetracycline in cholera. Gut 1987;28:1029–1032PubMedCrossRefGoogle Scholar
  142. 142.
    Grados P, Bravo N, Battilana C. Comparative effectiveness of co-trimoxazole and tetracycline in the treatment of cholera. Bull Pan Am Health Organ 1996;30:36–42PubMedGoogle Scholar

Copyright information

© Humana Press, a part of Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Michael L. Bennish
    • 1
  • Wasif A. Khan
    • 2
  • Debasish Saha
    • 3
  1. 1.Department of Population, Family and Reproductive Health, Bloomberg School of Public HealthJohns Hopkins UniversityBaltimoreSouth Africa
  2. 2.International Centre for Diarrhoeal Disease Research, Bangladesh (ICDDR, B)DhakaBangladesh
  3. 3.Bacterial Diseases ProgrammeMedical Research Council LaboratoriesThe GambiaWest Africa

Personalised recommendations